NCT05329168 (ERASE) is a Phase 2 clinical trial of Tonabacase (LSVT-1701) in Bacteremia Due to Staphylococcus Aureus, sponsored by Lysovant.

Who is sponsoring NCT05329168?

NCT05329168 is sponsored by Lysovant.

What drugs are being tested in NCT05329168?

Interventions in NCT05329168: Tonabacase (LSVT-1701).

What condition does NCT05329168 study?

NCT05329168 studies Bacteremia Due to Staphylococcus Aureus, Left Sided Infective Endocarditis (Disorder), Right Sided Infective Endocarditis (Disorder), Endocarditis Infective.

Is NCT05329168 still recruiting?

NCT05329168 is currently withdrawn. Last updated 30 June 2022.

Last reviewed 2022-06-30 · How we verify

NCT05329168: ERASE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis

Withdrawn Phase 2 Last updated 30 June 2022

What this trial tests

Phase 2 trial testing Tonabacase (LSVT-1701) in Bacteremia Due to Staphylococcus Aureus. Withdrawn.

Timeline

1 May 2022

Primary endpoint
17 August 2023

1 November 2023

Quick facts

Lead sponsor	Lysovant
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 May 2022
Primary completion	17 August 2023
Estimated completion	1 November 2023
Sites	1 location across United States

Drugs / interventions tested

Tonabacase (LSVT-1701) — full drug profile →

Conditions studied

Bacteremia Due to Staphylococcus Aureus — all drugs for Bacteremia Due to Staphylococcus Aureus →
Left Sided Infective Endocarditis (Disorder) — all drugs for Left Sided Infective Endocarditis (Disorder) →
Right Sided Infective Endocarditis (Disorder) — all drugs for Right Sided Infective Endocarditis (Disorder) →
Endocarditis Infective — all drugs for Endocarditis Infective →

Sponsor

Lysovant — full company profile →

Who can join

Adults 18 to 90, any sex, with Bacteremia Due to Staphylococcus Aureus or Left Sided Infective Endocarditis (Disorder). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates safety and tolerability of endolysin-derived LSVT-1701 (tonabacase) as an add-on to standard of care (SOC) antibiotic therapy for the treatment of patients with complicated Staphylococcus aureus bacteremia (SAB), including left- and right-sided infective endocarditis (IE).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Limitation of the Lytic Effect of Bacteriophages on <i>Salmonella</i> and Other Enteric Bacterial Pathogens and Approaches to Overcome.
Tung CW, Julianingsih D, Phan A, Canagarajah C, et al · · 2025 · cited 1× · PMID 40405891 · DOI 10.1155/ijm/5936070

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05329168 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lysovant
Last refreshed: 30 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05329168.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing